First-in-human Phase I/IIa, Open-Label, Prospective Study of the Safety and Tolerability of Subretinally Transplanted Human Retinal Progenitor Cells (hRPC) in Patients With Retinitis Pigmentosa (RP)
Phase of Trial: Phase I/II
Latest Information Update: 26 Mar 2018
At a glance
- Drugs ReN 003 (Primary)
- Indications Retinitis pigmentosa
- Focus Adverse reactions; First in man
- Sponsors ReNeuron
- 26 Mar 2018 According to a ReNeuron media release, short term read-outs from this trial is expected in the first half of 2019.
- 30 Jan 2018 Planned End Date changed from 1 Apr 2018 to 1 Nov 2018.
- 30 Jan 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Jul 2018.